Tocilizumab for Relapsing Polychondritis

Sponsor
McMaster Children's Hospital
Study ID
NCT01104480
Phase
PHASE2
Status
Withdrawn

Conditions

  • Relapsing Polychondritis

Eligibility Criteria

Sex
MALE
Age
12 Years - 15 Years
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Tocilizumab 8mg/kg every 2 weeks given by IV infusion

Study Details

This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.

Key Dates

Start date
May 31, 2010
Status verified
May 2014
Primary completion
Jul 31, 2010
Completion
May 31, 2012

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Efficacy of Tocilizumab [ Time Frame: 2 years ]

Related Studies